Bone Biologics Corporation is a medical device company focused on bone regeneration for spinal fusion using the recombinant human protein known as NELL 1 combined with demineralized bone matrix. The company’s lead product candidate, designated NB1, consists of NELL 1 protein mixed with DBM and is intended for use in lumbar interbody fusion procedures. Bone Biologics Corporation operates as a clinical stage entity and has conducted preclinical studies in sheep and non human…
Bone Biologics Corporation is a medical device company focused on bone regeneration for spinal fusion using the recombinant human protein known as NELL 1 combined with demineralized bone matrix. The company’s lead product candidate, designated NB1, consists of NELL 1 protein mixed with DBM and is intended for use in lumbar interbody fusion procedures. Bone Biologics Corporation operates as a clinical stage entity and has conducted preclinical studies in sheep and non human primate models as well as a first in human pilot clinical trial in Australia. Its technology was obtained via an exclusive worldwide license from the UCLA Technology Development Group and is regulated as a combination product requiring FDA pre market approval.
The company has not yet generated revenue from the sale of any medical device or biologic product. Its operations are financed primarily through equity offerings and capital raises that fund research development and clinical trial activities. Future revenue is expected to arise from the commercial sale of its NB1 product candidate and any associated licensing arrangements.
Bone Biologics Corporation operates in the highly competitive orthobiologics and spinal fusion markets where large established players such as Medtronic Stryker Globus Medical and DePuy Synthes dominate. The company differentiates itself through its exclusive worldwide license for the NELL 1 protein which provides a target specific mechanism of action aimed at reducing uncontrolled bone growth and inflammatory responses seen with competing products. Its preclinical data demonstrate increased fusion rates and a favorable safety profile in animal models which supports its potential to address unmet needs in spinal fusion and related orthopedic applications.
The company’s intended customers are spine surgeons orthopedic surgeons and hospitals that perform lumbar fusion procedures. Patients suffering from degenerative disc disease spondylolisthesis or other spinal bone defects represent the end user population that would benefit from the NB1 device. Additionally the technology may be applicable to trauma centers and physicians treating non union fractures or osteoporosis.